Status: Closed
Eligibility:

* Owner informed consent
* Client owned pet dogs
* Histologically confirmed malignant melanoma or myeloma
* Tumors must be objectively measurable using direct caliper measurement (documented by digital image and investigator documentation on evaluation form), ultrasound, radio-graphs or CT/MRI scan.
* Favorable clinical performance status at entry (expected to remain clinically stable for 30 days)
* No previous exposure to antiangiogenic therapies
* No chemotherapy within 14 days of trial entry
* No radiation therapy administered within 21 days of trial entry
* Corticosteroids and non-steroidal anti-inflammatory agents ok to continue if patient has been receiving for >14 days at time of study entry

Trial Support:
Antiangiogenic peptide will be provided at no charge. All examination, tumor imaging and other diagnostic costs are the patient”s responsibility, including a $50 monthly service fee ($50, billable to the Network clinic/investigator). All patients must be evaluated and treated monthly through a participating Animal Cancer Institute Network site. Diagnostic and staging tests may be performed at any veterinary hospital within 10 days of initiation (full serum chemistry, CBC, U/A and thoracic radiographs). Dogs will receive a month”s supply of medication for in-home, daily subcutaneous injection. Continued therapy will be available pending response to therapy.